Sylvie Rusakiewicz

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


16 publications

Sous presse
 
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N., Fortis E., Spathis A., Anastasiou M., Economopoulou P., Foukas GRP, Lelegiannis I.M., Rusakiewicz S., Vathiotis I., Aung T.N. et al. Annals of oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_77EE6FBCAC5B]
2024
 
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S., Tyekucheva S., Tissot-Renaud S., Chaba K., Imbimbo M., Benedetti F., Kammler R., Hornfeld J., Munzone E., Gianni L. et al., 2024/03. European journal of cancer, 200 p. 113535. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DE560AF185F]
2023
 
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_03AE420D2700]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
2022
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
 
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma.
Schaller J., Hajjami H.M., Rusakiewicz S., Ioannidou K., Piazzon N., Miles A., Golshayan D., Gaide O., Hohl D., Speiser D.E. et al., 2021/03/30. Oncotarget, 12 (7) pp. 638-648. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BF678E4FB907]
2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O'Brien M., Pope A., Fisher P., Spicer J., Roy A., Gilligan D. et al., 2020/12. Annals of oncology, 31 (12) pp. 1734-1745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0FC8052F2621]
 
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T. et al., 2020/12. Cytotherapy, 22 (12) pp. 780-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30851676B0A7]
 
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams S.F., Grimm A.J., Chiang C.L., Mookerjee A., Flies D., Jean S., McCann G.A., Michaux J., Pak H., Huber F. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e000875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B7CF92C7BCB]
2019
 
F-18-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F575C6723CE]
 
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95C8776874F3]
 
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.
Messaoudene M., Mourikis T.P., Michels J., Fu Y., Bonvalet M., Lacroix-Trikki M., Routy B., Fluckiger A., Rusakiewicz S., Roberti M.P. et al., 2019/06/01. Annals of oncology, 30 (6) pp. 934-944. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BF300CC80761]
2018
 
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer
Ivagnès Alexandre, Messaoudene Meriem, Stoll Gautier, Routy Bertrand, Fluckiger Aurélie, Yamazaki Takahiro, Iribarren Kristina, Duong Connie P. M., Fend Laetitia, Caignard Anne et al., 2018/12/02. OncoImmunology, 7 (12) pp. e1386826.
[DOI][WoS][serval:BIB_586AC3217BCD]
Cellular Composition and Contribution of Tertiary Lymphoid Structures to Tumor Immune Infiltration and Modulation by Radiation Therapy.
Boivin G., Kalambaden P., Faget J., Rusakiewicz S., Montay-Gruel P., Meylan E., Bourhis J., Lesec G., Vozenin M.C., 2018. Frontiers in oncology, 8 p. 256. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_64E7EAD7D9CF]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University